SVG Sprites


Press Releases 03.24.2020

Trump Administration gives Gilead greenlight to profiteer on promising COVID-19 Drug

Washington, DC (March 24, 2020) – Yesterday the Trump Administration gave the drug corporation Gilead Sciences special monopoly protection on the promising COVID-19 treatment Remdesivir, giving them a green light to price gouge on a desperately needed treatment.

Press Releases 03.20.2020

Statement: Drug Corporation Price-Gouged Potential Coronavirus Treatment

WASHINGTON (March 20, 2020) – Since the start of the coronavirus COVID-19 outbreak in the U.S. the Lower Drug Prices Now Coalition has been sounding the alarm about potential Big Pharma price gouging if President Trump and Health and Human Services Secretary Azar fail to enact price control measures that ensure affordability.

Press Releases 03.18.2020

Iowa Community Leaders want Guarantee that COVID-19 Vaccine and Treatments will be Accessible and Affordable to Everyone

(Des Moines, Iowa, March 18, 2020) — We hear a lot from national sources about the continuing needs, concerns and spread of the COVID-19 virus. Today we heard from real Iowans representing Iowa government, small business, healthcare, and senior communities about the effects in Iowa.

State Partner News 03.17.2020

Opinion: Joni Ernst seems more committed to working with Big Pharma than to lowering drug prices

Des Moines Register – 3/7/20

OPED by Patrick Morissey

State Partner News 03.16.2020

Collins Backing of Eli Lilly Exec to head health department gets renewed scrutiny

Maine Beacon – 3/16/20

As the Center for Disease Control (CDC) is inundated with criticism for its failure to adequately respond to the spread of COVID-19, Senator Susan Collins is now under fire for her 2018 vote to appoint Alex Azar — former president of pharmaceutical company Eli Lilly — to head the Department of Health and Human Services, which directly oversees the CDC.

Press Releases 03.12.2020

Statement: Trump’s Weak Insulin Ploy Does Nothing to Solve the Drug Pricing Crisis

Washington (March 12, 2020) – President Trump announced a new pilot project to cap insulin costs at $35 a month for people with diabetes participating in Medicare Part D. However, the proposed initiative is voluntary for drug makers and insurers and includes no controls on prices or negotiating power.

LDPN in the News 03.05.2020

Mainers share how much they pay for medication, call on Sen. Collins to take a stand

Maine Beacon – 3/5/20

At polls across Maine on Tuesday, hundreds of voters spoke with health care advocates and signed pledge cards calling on Sen. Susan Collins to do more to lower the cost of prescription drugs. Many Mainers punctuated their message by sharing how much they pay each month for their prescriptions, often totaling thousands of dollars.

Thank You for standing with us to put people before Pharma Profits!

Join our campaign, endorse our principles